Form 4: Corcept Officer Joseph Lyon Trades Shares

Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon reported multiple transactions involving company common stock, including option exercises, sales under a 10b5-1 plan, and acquisition of restricted stock awards.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported multiple transactions on September 2 and 3, 2025.
• Exercised 5,000 stock options at an exercise price of $13.56 per share.
• Sold a total of 5,000 shares of common stock (4,895 shares at a weighted average price of $70.2386 and 105 shares at a weighted average price of $70.7571) under a Rule 10b5-1 plan adopted on August 30, 2024.
• Acquired 200 shares of common stock at $71.38 per share through a company Purchase Plan.
• Received 200 shares as unvested restricted stock awards under the Purchase Plan, which will vest on the one-year anniversary of the grant date.
• 189 shares were withheld by the Issuer to satisfy tax withholding obligations related to the vesting of restricted stock units, calculated at a closing price of $71.38 per share.
• Following these transactions, Lyon directly beneficially owns 10,277 shares of common stock, which includes 1,380 shares underlying unvested restricted stock awards.
• Lyon also holds 26,571 exercisable stock options.

Sentiment

Score: 5

Explanation: The transactions represent a mix of option exercises and share acquisitions, alongside sales under a pre-arranged plan, indicating a balanced insider activity without a clear strong positive or negative signal.

Positives

• Officer Joseph Douglas Lyon exercised 5,000 stock options at $13.56, indicating a potential positive outlook on the company's future performance.
• Acquired 200 shares of common stock at $71.38 through a company Purchase Plan, further aligning his interests with shareholders.
• Received 200 shares as unvested restricted stock awards, demonstrating continued incentive alignment with the company's long-term success.

Negatives

• Officer Joseph Douglas Lyon sold a total of 5,000 shares of common stock (4,895 shares at a weighted average price of $70.2386 and 105 shares at a weighted average price of $70.7571), which could be perceived as a reduction in direct exposure to the company's stock.
• 189 shares were withheld by the Issuer to satisfy tax withholding obligations, reducing the net shares received from vesting restricted stock units.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Insider transactions can influence investor sentiment. Sales might be viewed negatively, while option exercises and purchases could be seen positively, reflecting management's confidence or compensation structure.

Next Steps

• Vesting of 215 restricted stock awards on December 2, 2025 (one-year anniversary of grant).
• Vesting of 216 restricted stock awards on March 3, 2026 (one-year anniversary of grant).
• Vesting of 749 restricted stock awards on June 2, 2026 (one-year anniversary of grant).
• Vesting of 200 restricted stock awards on September 2, 2026 (one-year anniversary of grant), contingent on beneficial ownership of Purchase Plan Shares.

Key Dates

Recommendation

The Form 4 details routine insider transactions, including both acquisitions and sales under a 10b5-1 plan. While the sales reduce direct shareholding, the option exercise and new share acquisitions demonstrate continued alignment with company performance. These transactions do not provide sufficient new information to warrant a change in investment stance, thus a 'hold' recommendation is appropriate for investors awaiting broader financial or strategic updates.

Keywords

CORT, Corcept Therapeutics, Insider Trading, Form 4, Stock Option, Share Sale, Restricted Stock, Joseph Douglas Lyon